Enrica T. Tanda
A5011850347- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Immune cells in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Ocular Oncology and Treatments
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Nonmelanoma Skin Cancer Studies
- Renal Transplantation Outcomes and Treatments
- Diabetes and associated disorders
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Medication Adherence and Compliance
Ospedale Policlinico San Martino
2016-2025
University of Genoa
2015-2024
Alleanza Contro il Cancro
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2016
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on outcomes, by weighing their associations baseline characteristics (including performance status, burden disease body mass index) underlying causes for prescription. This analysis included consecutive...
In recent years, advances in melanoma treatment have renewed patient hope. This comprehensive review emphasizes the evolving landscape, particularly highlighting first-line strategies and interplay between immune-checkpoint inhibitors (ICIs) targeted therapies. Ipilimumab plus nivolumab has achieved best median overall survival, exceeding 70 months. However, introduction of new ICIs, like relatlimab, added complexity to therapy decisions. Our aim is guide clinicians making personalized...
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Background Immune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in last decades, improving outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking immune pathways, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) with its ligand PD-L1. However, activation response can cause a broad range side effects, called immune-related adverse events (irAEs). Endocrine irAEs mainly...
The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet be determined. Multigene panel testing could increase diagnostic yield and better define the role genes. We characterized 273 CDKN2A/ARF CDK4-negative probands through a custom-designed targeted gene that included CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1, TERF2IP, ATM, PALB2. Co-segregation, loss heterozygosity (LOH)/protein expression analysis, splicing characterization were...
Abstract Background The p.E318K variant of the Melanocyte Inducing Transcription Factor ( MITF ) has been implicated in genetic predisposition to melanoma as an intermediate penetrance allele. However, impact this on clinico-phenotypic, well dermoscopic patterns features affected patients is not entirely defined. purpose our study was assess association between germline and clinic-phenotypical + compared non-carriers −), including findings melanomas dysplastic nevi. Methods we...